[Ip-health] MSF responds to Indian Supreme Court decision upholding production of affordable cancer drug
shailly.gupta at geneva.msf.org
Fri Dec 12 21:08:57 PST 2014
MSF responds to Indian Supreme Court decision upholding production of affordable cancer drug
On 12 December the Indian Supreme Court rejected Bayer’s appeal to block production and sales of a lower-cost version of its exorbitantly expensive cancer medication, sorafenib tosylate (marketed as Nexavar).
Since 2012, the Indian generic company Natco has been allowed to produce an affordable generic version of Bayer’s cancer drug, which at US$5,500 per person, per month in India, was deemed unaffordable by the Indian Patent Office. At that time, the Indian Patent Office granted Natco the country’s first-ever compulsory license (CL) as a way to make the medicine more accessible: the move was effective in bringing down the price by 97% to $175 per person, per month, in exchange for which Natco pays Bayer a royalty fee. Bayer has been appealing the decision ever since, but today’s Supreme Court’s decision, which upholds the legal validity of the CL and dismisses Bayer’s Special Leave Petition, is a major win for public health and concludes the legal proceedings on the CL.
Médecins Sans Frontières responds to the news of the decision
“Amidst intense ongoing US government pressure tactics being waged on India on behalf of the US pharmaceutical industry, today’s Indian Supreme Court decision demonstrates the independence of the Indian judiciary in upholding India’s right to legislate with public health interests in mind.
“MSF is encouraged by this particularly strategic win for public health and access to medicines, whereby the Supreme Court has worked to ensure continued patient access to affordable versions of this lifesaving cancer drug, in spite of a multi-year campaign by Bayer to reverse the decision.
“It was clear not only to MSF but also to the Indian judiciary that Bayer’s so-called patient access programme was reaching only around 2% of patients in need, and that furthermore, Bayer’s full R&D costs for development of the drug had been recouped in just one year. In response, the Indian government used legal flexibilities allowed in international law to jumpstart generic production, so that a patent-based monopoly on the drug would not be the culprit standing in the way of saving lives.
“Today we applaud this heartening news, which reaffirms India’s critical role in forging a new and progressive path in balancing intellectual property and public health.”
-- Leena Menghaney, Regional Head - South Asia, MSF Access Campaign
MSF Access Campaign
More information about the Ip-health